For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Allogene Therapeutics, Inc.

USPTO Granted Patents = 17

EPO Patents = 4

Trademarks = 10

Forward Citations = 9

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Barbra Johnson Sasu (11 out of 25 patents)

Thomas John Van Blarcom (8 out of 23 patents)

Thomas Charles Pertel (6 out of 9 patents)

4. Siler Panowski (5 out of 10 patents)

5. Yi Zhang (3 out of 3 patents)

6. Regina Junhui Lin (3 out of 4 patents)

7. Mark W Leonard (3 out of 3 patents)

8. Michael Thomas Bethune (2 out of 2 patents)

9. Yajin Ni (2 out of 2 patents)

10. Laurent Poirot (1 out of 35 patents)

11. Tao Sai (1 out of 15 patents)

12. Arvind Rajpal (1 out of 44 patents)

13. Meritxell Galindo Casas (1 out of 3 patents)

14. Javier Fernando Chaparro Riggers (1 out of 20 patents)

15. Cesar Adolfo Sommer (1 out of 7 patents)

17 patents: Sort by Forward Citations

1. 12447178 - Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors (2025-10-21),

2. 12404315 - Protease-activating CD45-gate CAR (2025-09-02),

3. 12365873 - Methods for transducing immune cells (2025-07-22),

4. 12295362 - Formulations and processes for CAR T cell drug products (2025-05-13),

5. 12221462 - Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells (2025-02-11),

6. 12215347 - Chimeric antigen receptors with enhanced signaling and activities and uses thereof (2025-02-04),

7. 12163169 - Inducible chimeric cytokine receptors (2024-12-10),

8. 12163153 - Methods of manufacturing allogeneic CAR T cells (2024-12-10),

9. 12104188 - Modified caspase-9 polypeptides and methods of use thereof (2024-10-01),

10. 12043655 - Constitutively active chimeric cytokine receptors (2024-07-23),

11. 12036243 - BCMA CAR-T cells with enhanced activities (2024-07-16),

12. 11896617 - Polynucleotides encoding rituximab-resistant chimeric antigen receptors (2024-02-13),

13. 11781248 - Anti-TALEN antibodies and uses thereof (2023-10-10),

14. 11732041 - Antibodies against 4G7-derived chimeric antigen receptors (2023-08-22),

15. 11673953 - DLL3 targeting chimeric antigen receptors and binding agents (2023-06-13),

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (CAR T) therapy for cancer. The company is focused on developing potentially curative therapies for patients with hematologic malignancies and solid tumors.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

17 Patents

#73 in South San Francisco, CA

#4,375 in California

#18,330 in US

#34,859 in the World

South San Francisco, CA, United States of America

Allogene Therapeutics, Inc.

Forward Citations = 9

38 inventors:

Barbra Johnson Sasu (11 out of 25 patents)

Thomas John Van Blarcom (8 out of 23 patents)

Thomas Charles Pertel (6 out of 9 patents)

4. Siler Panowski (5 out of 10 patents)

5. Yi Zhang (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…